Chemist + Druggist is part of Pharma Intelligence UK Limited

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.


This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction

PSNC: Cat M clawback and cuts make for 'difficult' year

Contractors should start preparing for a £48 million reduction in category M payments across June to September, negotiator advises

A newly-announced category M clawback coupled with planned cuts to pharmacy funding will make this financial year “very difficult” for contractors, the Pharmaceutical Services Negotiating Committee (PSNC) has warned.

The Department of Health (DH) has decided to reduce category M payments by a total of £48 million between June and September (see more below), in response to data it believes shows contractors were paid more than the agreed sum for 2015-16, PSNC said today (May 13).

PSNC admitted that there was a “major over-delivery of margin" in 2015-16, but stressed that it had not agreed to the level of clawback. 

The chair of the negotiator's funding and contract subcommittee Peter Cattee “strongly advised” contractors to start preparing for the funding reductions now.

"Earnings from the first half of this financial year will be adversely affected by the [clawback], but will still be significantly above those expected for the second half," he said.

Government “unshaken” in plans to cut funding

The government had shown itself to be “unshaken” in its plans to slash £170m from the sector’s funding and plans to do this by reducing fees and allowances, the negotiator added.

PSNC is “very pessimistic” about the outcome of the government’s consultation on the cuts – due to close on May 24 – it said. The government has shown “little interest” in PSNC’s “constructive” cost-saving counter proposals, which include dispensing generic versions of branded drugs and a month-long campaign to raise awareness of medicines waste, it added.

Category M clawback – how much and when?

The DH announced today that it will reduce category M prices by £12m per month from June to September, to make up for what it views as excess margin that was paid to contractors over the agreed sum of £800m for 2015-16.

It believes that preliminary data it has analysed from the 2015-16 medicines margin survey is “robust enough” to justify the £48m clawback for the four-month period, it told PSNC in a letter.

The DH will review category M payments for October onwards in consultation with PSNC, once it has the final results from the survey. The DH's projections suggest that drug prices in October are "unlikely to see a significant recovery”, PSNC warned contractors.

The drug tariff will be amended to reflect the new prices and June 2016 prices will be available shortly on the NHS prescription services website, PSNC added.

Scottish contractors saw their funding increase this week. Find out by how much here.
 

How will the category M clawback affect your business?

We want to hear your views, but please express them in the spirit of a constructive, professional debate. For more information about what this means, please click here to see our community principles and information

Related Content

Topics

         
Pharmacist Manager
Barnsley
£30 per hour

Apply Now
Latest News & Analysis
See All
UsernamePublicRestriction

Register

CD008124

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel